期刊文献+

卵巢癌鉴别诊断及术前分期评估中磁共振成像的价值分析

Value of Magnetic Resonance Imaging in Differential Diagnosis and Preoperative Staging Evaluation of Ovarian Cancer
下载PDF
导出
摘要 目的该文探讨通过有效的诊断方法进行诊断,并给予术前分期评估,以利于患者疾病的治疗。方法参与该次实验的患者均为方便选取该院进行卵巢肿瘤治疗的患者59例,收入患者时间为2018年1月—2019年6月,参与该次实验的患者均经手术证实,确诊卵巢癌,并完成术前分期,全部患者在治疗期间均采用磁共振进行检查与诊断,将磁共振检查结果与手术病理结果进行比较。结果与手术病理结果相比,磁共振卵巢癌诊断准确率(94.92%)、分期符合率(94.29%)数据,差异无统计学意义(χ^2=1.078,2.059,P=0.079,0.151)。结论磁共振在卵巢癌确诊方面可起到较为显著的效果,具有较高的应用价值,同时可对卵巢癌进行术前分期,为患者治疗提供重要依据。 Objective The paper discusses that it*should be diagnosed by effective diagnostic methods and given preoperative staging evaluation to facilitate the treatment of patients'diseases.Methods The patients participating in this experiment were 59 patients who came to our hospital for ovarian tumor treatment,and the income patients were convenient selection from January 2018 to June 2019.All patients participating in this experiment were confirmed by surgery and confirmed ovarian cancer,and completed the preoperative staging,all patients were examined and diagnosed with magnetic resonance during the treatment,and the magnetic resonance examination results were compared with the surgical pathological results.Results Compared with the surgical pathological results,the diagnostic accuracy rate(94.92%)and staging coincidence rate(94.29%)of magnetic resonance ovarian cancer were not different,and there was no statistical significance(χ^2=1.078,2.059,P=0.079,0.151).Conclusion Magnetic resonance imaging can play a significant role in the diagnosis of ovarian cancer,and has high application value.It can also perform preoperative staging of ovarian cancer and provide important evidence for patient treatment.
作者 王玉 WANG Yu(Department of Magnetic Resonance,Guanxian People's Hospital,Guanxian,Shandong Province,252500 China)
出处 《中外医疗》 2020年第16期4-6,共3页 China & Foreign Medical Treatment
关键词 卵巢癌 术前分期 磁共振 成像 价值 Ovarian cancer Preoperative staging Magnetic resonance Imaging Value
  • 相关文献

参考文献5

二级参考文献43

  • 1韩东明,杨秀萍,王红坡,李玉侠.CT和MRI对卵巢肿瘤的诊断价值比较[J].中国临床医学影像杂志,2005,16(8):441-443. 被引量:17
  • 2Zhang Z, Barnhill SD, Zhang H, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol, 1999,73:56-61.
  • 3Woolas RP, Xu FJ, Jacobs IJ, et al. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst, 1993, 85:1748-1751.
  • 4Schutter EM, Davelaar EM, van Kamp GJ, et al. The differential diagnostic potential of a panel of turnout markers (CA125, CA15-3, and CA72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol, 2002, 187: 385-392.
  • 5Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol, 1995,59 : 111-116.
  • 6Woolas RP, Conaway MR, Xu F, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol, 1995,59 : 111-116.
  • 7van Haahen-Day C, Shen Y, Xu F, et al. OVX1, macrophage-colony stimu- lating factor, and CA-125-II as tumour markers for epithelial ovarian carcinoma : a critical appraisal. Cancer, 2001,92 : 2837-2844.
  • 8Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene, 1999,238 : 375-385.
  • 9Galgano MT, Hampton GM, Frierson HF, et al. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol, 2006, 19 : 847-53.
  • 10Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res, 2003,63 : 3695- 3700.

共引文献120

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部